Imperial College London
Portrait Picture

Professor Hashim Ahmed

Faculty of Medicine, Department of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Connor:2022:10.1016/j.euros.2021.10.003,
author = {Connor, MJ and Genie, MG and Burns, D and Bass, EJ and Gonzalez, M and Sarwar, N and Falconer, A and Mangar, S and Dudderidge, T and Khoo, V and Winkler, M and Ahmed, HU and Watson, V},
doi = {10.1016/j.euros.2021.10.003},
journal = {European Urology Open Science},
pages = {9--18},
title = {A systematic review of patients' values, preferences, and expectations for the treatment of metastatic prostate cancer},
url = {http://dx.doi.org/10.1016/j.euros.2021.10.003},
volume = {36},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Context: Advances in systemic agents have increased overall survival for men diagnosed with metastatic prostate cancer. Additional cytoreductive prostate treatments and metastasis-directed therapies are under evaluation. These confer toxicity but may offer incremental survival benefits. Thus, an understanding of patients' values and treatment preferences is important for counselling, decision-making, and guideline development. Objective: To perform a systematic review of patients' values, preferences, and expectations regarding treatment of metastatic prostate cancer. Evidence acquisition: The MEDLINE, Embase, and CINAHL databases were systematically searched for qualitative and preference elucidation studies reporting on patients' preferences for treatment of metastatic prostate cancer. Certainty of evidence was assessed using Grading of Recommendation, Assessment, Development and Evaluation (GRADE) or GRADE Confidence in the Evidence from Reviews of Qualitative Research (CERQual). The protocol was registered on PROSPERO as CRD42020201420. Evidence synthesis: A total of 1491 participants from 15 studies met the prespecified eligibility for inclusion. The study designs included were discrete choice experiments (n = 5), mixed methods (n = 3), and qualitative methods (n = 7). Disease states reported per study were: metastatic castration-resistant prostate cancer in nine studies (60.0%), metastatic hormone-sensitive prostate cancer in two studies (13.3%), and a mixed cohort in four studies (26.6%). In quantitative preference elicitation studies, patients consistently valued treatment effectiveness and delay in time to symptoms as the two top-ranked treatment attributes (low or very low certainty). Patients were willing to trade off treatment-related toxicity for potential oncological benefits (low certainty). In qualitative studies, thematic analysis revealed cancer progression and/or survival, pain, and fatigue as key components in treatment decisions (low or very low
AU  - Connor,MJ
AU  - Genie,MG
AU  - Burns,D
AU  - Bass,EJ
AU  - Gonzalez,M
AU  - Sarwar,N
AU  - Falconer,A
AU  - Mangar,S
AU  - Dudderidge,T
AU  - Khoo,V
AU  - Winkler,M
AU  - Ahmed,HU
AU  - Watson,V
DO  - 10.1016/j.euros.2021.10.003
EP  - 18
PY  - 2022///
SN  - 2666-1683
SP  - 9
TI  - A systematic review of patients' values, preferences, and expectations for the treatment of metastatic prostate cancer
T2  - European Urology Open Science
UR  - http://dx.doi.org/10.1016/j.euros.2021.10.003
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34977691
UR  - http://hdl.handle.net/10044/1/93502
VL  - 36
ER  -
Download